The DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.
Pharmacokinetics of Monoclonal Antibodies
Open accessAbstract
Monoclonal antibodies (mAbs) have developed in the last two decades into the backbone of pharmacotherapeutic interventions in a variety of indications, with currently more than 40 mAbs approved by the US Food and Drug Administration, and several dozens more in clinical development. This tutorial will review major drug disposition processes relevant for mAbs, and will highlight product‐specific and patient‐specific factors that modulate their pharmacokinetic (PK) behavior and need to be considered for successful clinical therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Continuous cultures of fused cells secreting antibody of predefined specificity
KÖHLER, G., & MILSTEIN, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,229
Fcγ receptors as regulators of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947
IgG Subclasses and Allotypes: From Structure to Effector Functions
Vidarsson, G., Dekkers, G., & Rispens, T. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00520 · Cited by 2,667
FcRn: the neonatal Fc receptor comes of age
Roopenian, D. C., & Akilesh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2155 · Cited by 2,346
Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation
Kaneko, Y., Nimmerjahn, F., & Ravetch, J. V. (2006) · Science · doi:10.1126/science.1129594 · Cited by 1,754
Musolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8957 · Cited by 981
Comparing antibody and small-molecule therapies for cancer
Imai, K., & Takaoka, A. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1913 · Cited by 792
The physiology of the lymphatic system
Swartz, M. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00150-8 · Cited by 737
Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies
Keizer, R. J., Huitema, A. D. R., Schellens, J. H. M., & Beijnen, J. H. (2010) · Clinical Pharmacokinetics · doi:10.2165/11531280-000000000-00000 · Cited by 725
Waldmann, T. A., & Strober, W. (2015) · Chemical Immunology and Allergy · doi:10.1159/000385919 · Cited by 723
Junghans, R. P., & Anderson, C. L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.11.5512 · Cited by 684
CNS Delivery Via Adsorptive Transcytosis
Hervé, F., Ghinea, N., & Scherrmann, J.-M. (2008) · The AAPS Journal · doi:10.1208/s12248-008-9055-2 · Cited by 676
General Pharmacokinetic Model for Drugs Exhibiting Target-Mediated Drug Disposition
Mager, D. E., & Jusko, W. J. (2001) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1023/a:1014414520282 · Cited by 605
Strategies for extended serum half-life of protein therapeutics
Kontermann, R. E. (2011) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2011.06.012 · Cited by 573
Immunogenicity of therapeutic proteins: Clinical implications and future prospects
Schellekens, H. (2002) · Clinical Therapeutics · doi:10.1016/s0149-2918(02)80075-3 · Cited by 556
Metabolic properties of IgG subclasses in man
Morell, A., Terry, W. D., & Waldmann, T. A. (1970) · Journal of Clinical Investigation · doi:10.1172/jci106279 · Cited by 526
Ober, R. J., Radu, C. G., Ghetie, V., & Ward, E. S. (2001) · International Immunology · doi:10.1093/intimm/13.12.1551 · Cited by 501
Population Pharmacokinetics of Therapeutic Monoclonal Antibodies
Dirks, N. L., & Meibohm, B. (2010) · Clinical Pharmacokinetics · doi:10.2165/11535960-000000000-00000 · Cited by 500
Self-citationOrdás, I., Mould, D. R., Feagan, B. G., & Sandborn, W. J. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.328 · Cited by 498
A Theoretical Model of γ-Globulin Catabolism
BRAMBELL, F. W. R., HEMMINGS, W. A., & MORRIS, I. G. (1964) · Nature · doi:10.1038/2031352a0 · Cited by 449
Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line
Dickinson, B. L., Badizadegan, K., Wu, Z., Ahouse, J. C., Zhu, X., Simister, N. E., Blumberg, R. S., & Lencer, W. I. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6968 · Cited by 434
Shah, D. K., & Betts, A. M. (2012) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-011-9232-2 · Cited by 422
Khawli, L. A., Goswami, S., Hutchinson, R., Kwong, Z. W., Yang, J., Wang, X., Yao, Z., Sreedhara, A., Cano, T., Tesar, D. B., et al. (2010) · mAbs · doi:10.4161/mabs.2.6.13333 · Cited by 419
Gessner, J. E., Heiken, H., Tamm, A., & Schmidt, R. E. (1998) · Annals of Hematology · doi:10.1007/s002770050396 · Cited by 404
Fc glycans of therapeutic antibodies as critical quality attributes
Reusch, D., & Tejada, M. L. (2015) · Glycobiology · doi:10.1093/glycob/cwv065 · Cited by 404
Effects of Charge on Antibody Tissue Distribution and Pharmacokinetics
Boswell, C. A., Tesar, D. B., Mukhyala, K., Theil, F.-P., Fielder, P. J., & Khawli, L. A. (2010) · Bioconjugate Chemistry · doi:10.1021/bc100261d · Cited by 398
Mechanistic Determinants of Biotherapeutics Absorption Following SC Administration
Richter, W. F., Bhansali, S. G., & Morris, M. E. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9367-0 · Cited by 377
Cancer and systemic inflammation: treat the tumour and treat the host
Roxburgh, C. S. D., & McMillan, D. C. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.90 · Cited by 368
Higel, F., Seidl, A., Sörgel, F., & Friess, W. (2016) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2016.01.005 · Cited by 360
Hirayama, C. (1968) · SEIBUTSU BUTSURI KAGAKU · doi:10.2198/sbk.13.201 · Cited by 347
Immunogenicity to Therapeutic Proteins: Impact on PK/PD and Efficacy
Chirmule, N., Jawa, V., & Meibohm, B. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9340-y · Cited by 335
Self-citationPharmacokinetics of monoclonal immunoglobulin G1, F(ab')2, and Fab' in mice.
Covell, D. G., Barbet, J., Holton, O. D., BLACK, C. D. V., Parker, R. J., & Weinstein, J. N. (1986) · PubMed · Cited by 311
Advances in the assessment and control of the effector functions of therapeutic antibodies
Jiang, X.-R., Song, A., Bergelson, S., Arroll, T., Parekh, B., May, K., Chung, S., Strouse, R., Mire-Sluis, A., & Schenerman, M. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3365 · Cited by 299
The renal handling of low molecular weight proteins
Waldmann, T. A., Strober, W., & Mogielnicki, R. P. (1972) · Journal of Clinical Investigation · doi:10.1172/jci107023 · Cited by 284
Baxter, L. T., Zhu, H. J., Mackensen, D. G., & Jain, R. K. (1994) · PubMed · Cited by 284
Gibney, M. A., Arce, C. H., Byron, K. J., & Hirsch, L. J. (2010) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.481203 · Cited by 283
A strategy for risk mitigation of antibodies with fast clearance
Hötzel, I., Theil, F.-P., Bernstein, L. J., Prabhu, S., Deng, R., Quintana, L., Lutman, J., Sibia, R., Chan, P., Bumbaca, D., et al. (2012) · mAbs · doi:10.4161/mabs.22189 · Cited by 245
Junttila, T. T., Parsons, K., Olsson, C., Lu, Y., Xin, Y., Theriault, J., Crocker, L., Pabonan, O., Baginski, T., Meng, G., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3704 · Cited by 221
Kim, J., Hayton, W. L., Robinson, J. M., & Anderson, C. L. (2007) · Clinical Immunology · doi:10.1016/j.clim.2006.09.001 · Cited by 208
Yu, M., Brown, D., Reed, C., Chung, S., Lutman, J., Stefanich, E., Wong, A., Stephan, J.-P., & Bayer, R. (2012) · mAbs · doi:10.4161/mabs.20737 · Cited by 203
Antohe, F., Rădulescu, L., Gafencu, A., Gheţie, V., & Simionescu, M. (2001) · Human Immunology · doi:10.1016/s0198-8859(00)00244-5 · Cited by 175
Production of therapeutic antibodies with controlled fucosylation
Yamane-Ohnuki, N., & Satoh, M. (2009) · mAbs · doi:10.4161/mabs.1.3.8328 · Cited by 170
Immunogenicity to Biologics: Mechanisms, Prediction and Reduction
Sethu, S., Govindappa, K., Alhaidari, M., Pirmohamed, M., Park, K., & Sathish, J. G. (2012) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-012-0189-7 · Cited by 168
A Tutorial on Target-Mediated Drug Disposition (TMDD) Models
Dua, P., Hawkins, E., & van der Graaf, P. (2015) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.41 · Cited by 162
Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies
Cao, Y., Balthasar, J. P., & Jusko, W. J. (2013) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-013-9332-2 · Cited by 161
McCarthy, K. M., Yoong, Y., & Simister, N. E. (2000) · Journal of Cell Science · doi:10.1242/jcs.113.7.1277 · Cited by 155
Zheng, Y., Tesar, D. B., Benincosa, L., Birnböck, H., Boswell, C. A., Bumbaca, D., Cowan, K. J., Danilenko, D. M., Daugherty, A. L., Fielder, P. J., et al. (2012) · mAbs · doi:10.4161/mabs.4.2.19387 · Cited by 149
Reddy, S. T., Berk, D. A., Jain, R. K., & Swartz, M. A. (2006) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00389.2006 · Cited by 145
Claypool, S. M., Dickinson, B. L., Wagner, J. S., Johansen, F.-E., Venu, N., Borawski, J. A., Lencer, W. I., & Blumberg, R. S. (2004) · Molecular Biology of the Cell · doi:10.1091/mbc.e03-11-0832 · Cited by 139
Jones, A. J. S., Papac, D. I., Chin, E. H., Keck, R. G., Baughman, S. A., Lin, Y. S., Kneer, J., & Battersby, J. E. (2007) · Glycobiology · doi:10.1093/glycob/cwm017 · Cited by 137
Lung uptake of antibodies to endothelial antigens: key determinants of vascular immunotargeting
Danilov, S. M., Gavrilyuk, V., Franke, F. E., Pauls, K., Harshaw, D. W., McDonald, T. D., Miletich, D. J., & Muzykantov, V. R. (2001) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.2001.280.6.l1335 · Cited by 135
Subcutaneous administration of biotherapeutics: current experience in animal models.
McDonald, T. A., Zepeda, M. L., Tomlinson, M. J., Bee, W. H., & Ivens, I. A. (2010) · PubMed · Cited by 135
Zhao, L. Y., Ji, P., Li, Z., Roy, P., & Sahajwalla, C. G. (2013) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.4 · Cited by 128
Sachs, U. J., Socher, I., Braeunlich, C. G., Kroll, H., Bein, G., & Santoso, S. (2006) · Immunology · doi:10.1111/j.1365-2567.2006.02408.x · Cited by 128
Efflux of monoclonal antibodies from rat brain by neonatal Fc receptor, FcRn
Cooper, P. R., Ciambrone, G. J., Kliwinski, C. M., Maze, E., Johnson, L., Li, Q., Feng, Y., & Hornby, P. J. (2013) · Brain Research · doi:10.1016/j.brainres.2013.08.035 · Cited by 127
Deng, R., Jin, F., Prabhu, S., & Iyer, S. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.643868 · Cited by 126
Olszewski, W. L., Engeset, A., Icger, P. M., Sokołowski, J., & Theodorsen, L. (1977) · Acta Physiologica Scandinavica · doi:10.1111/j.1748-1716.1977.tb10365.x · Cited by 126
Azzopardi, N., Lecomte, T., Ternant, D., Boisdron-Celle, M., Piller, F., Morel, A., Gouilleux‐Gruart, V., Desvignes, C., Watier, H., Gamelin, E. C., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1081 · Cited by 119
Wright, A. M., Sato, Y., Okada, T., Chang, K. H., Endo, T., & Morrison, S. L. (2000) · Glycobiology · doi:10.1093/glycob/10.12.1347 · Cited by 119
Influence of whole body protein turnover rate on resting energy expenditure in patients with cancer.
Fearon, K. C. H., HANSELL, D. T., Preston, T., Plumb, J. A., Davies, J., Shapiro, D. M., Shenkin, A., Calman, K. C., & Burns, H. J. G. (1988) · PubMed · Cited by 118
T cell epitope: Friend or Foe? Immunogenicity of biologics in context☆
Weber, C. A., Mehta, P. J., Ardito, M. T., Moise, L., Martin, B., & Groot, A. S. D. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.07.001 · Cited by 114
Deng, R., Loyet, K. M., Lien, S., Iyer, S., DeForge, L. E., Theil, F., Lowman, H. B., Fielder, P. J., & Prabhu, S. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.031310 · Cited by 112
Gill, K. L., Gardner, I. B., Li, L., & Jamei, M. (2015) · The AAPS Journal · doi:10.1208/s12248-015-9819-4 · Cited by 110
Drug Development of Therapeutic Monoclonal Antibodies
Mould, D. R., & Meibohm, B. (2016) · BioDrugs · doi:10.1007/s40259-016-0181-6 · Cited by 110
Self-citationCosson, V. F., Ng, V., Lehle, M., & Lum, B. L. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2400-5 · Cited by 107
Kagan, L., Turner, M. R., Balu‐Iyer, S. V., & Mager, D. E. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0578-3 · Cited by 106
Population Pharmacokinetic Analysis of Panitumumab in Patients With Advanced Solid Tumors
Ma, P., Yang, B., Wang, Y., Peterson, M. C., Narayanan, A., Sutjandra, L., Rodriguez, R. D., & Chow, A. T. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009344989 · Cited by 91
Flessner, M. F., Lofthouse, J., & Zakaria, E. R. (1997) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.1997.273.6.h2783 · Cited by 83
Albitar, M. X., Do, K.-A., Johnson, M. M., Giles, F. J., Jilani, I. B., O'Brien, S. M., Cortes, J. E., Thomas, D. A., Rassenti, L. Z., Kipps, T. J., et al. (2004) · Cancer · doi:10.1002/cncr.20477 · Cited by 79
Mechanisms of Intravenous Immunoglobulin Action in Immune Thrombocytopenic Purpura
Jin, F., & Balthasar, J. P. (2005) · Human Immunology · doi:10.1016/j.humimm.2005.01.029 · Cited by 78
Trotta, A. M., Ottaiano, A., Romano, C., Nasti, G., Nappi, A. G., Divitiis, C. D., Napolitano, M., Zanotta, S., Casaretti, R., D’Alterio, C., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0184 · Cited by 78
Gouilleux‐Gruart, V., Chapel, H. M., Chevret, S., Lucas, M., Malphettes, M., Fieschi, C., Patel, S. Y., Boutboul, D., Marson, M.-N., Gérard, L., et al. (2012) · Clinical & Experimental Immunology · doi:10.1111/cei.12002 · Cited by 77
Kobayashi, H., Le, N., Kim, I. S., Kim, M. K., Pie, J.-E., Drumm, D., Paik, D. S., Waldmann, T. A., Paik, C. H., & Carrasquillo, J. A. (1999) · PubMed · Cited by 73
Keck, R. G., Nayak, N., Lerner, L. E., Raju, S., Ma, S., Schreitmueller, T., Chamow, S., Moorhouse, K., Kotts, C. E., & Jones, A. J. S. (2007) · Biologicals · doi:10.1016/j.biologicals.2007.05.004 · Cited by 72
Berdeja, J. G., Jagannath, S., Zonder, J. A., Badros, A. Z., Kaufman, J. L., Manges, R., Gupta, M., Tendolkar, A. V., Lynch, M. J., Bleickardt, E. W., et al. (2015) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2015.12.007 · Cited by 70
Billiet, T., Dreesen, E., Cleynen, I., Wollants, W.-J., Ferrante, M., Assche, G. V., Gils, A., & Vermeire, S. (2016) · The American Journal of Gastroenterology · doi:10.1038/ajg.2016.306 · Cited by 70
Kota, J., Machavaram, K. K., McLennan, D. N., Edwards, G. A., Porter, C. J. H., & Charman, S. A. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.015669 · Cited by 67
Clinical investigation of the immunogenicity of interferon-alpha 2a.
Ryff, J. ‐. (1997) · PubMed · Cited by 67
Differential clearance of glycoforms of IgG in normal and autoimmune-prone mice
Newkirk, M. M., Novick, J., Stevenson, M. M., Fournier, M.-J., & Apostolakos, P. (1996) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.1996.d01-847.x · Cited by 66
Davda, J. P., Dodds, M., Gibbs, M. A., Wisdom, W., & Gibbs, J. P. (2014) · mAbs · doi:10.4161/mabs.29095 · Cited by 53
Wang, Y., Booth, B., Rahman, A., Kim, G., Huang, S., & Zineh, I. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.628 · Cited by 48
New targets for drug delivery across the BBB
Kingwell, K. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.14 · Cited by 48
Recombinant Human Interferon Alpha-2a: Delivery to Lymphoid Tissue by Selected Modes of Application
Supersaxo, A., Hein, W., Gallati, H., & Steffen, H. (1988) · Pharmaceutical Research · doi:10.1023/a:1015957022073 · Cited by 46
Assessments of antibody biodistribution
Glassman, P. M., Abuqayyas, L., & Balthasar, J. P. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.365 · Cited by 42
van den Bemt, B. J. F., den Broeder, A. A., Wolbink, G., Hekster, Y. A., van Riel, P. L. C. M., Benraad, B., & van den Hoogen, F. H. J. (2011) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-12-12 · Cited by 42
Physiologically Based Pharmacokinetic Modeling of Therapeutic Proteins
Wong, H. H., & Chow, T. W. (2017) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2017.03.038 · Cited by 42
Human platelet FcγRIIA and phagocytes in immune-complex clearance
Huang, Z.-Y., Chien, P., Indik, Z. K., & Schreiber, A. D. (2010) · Molecular Immunology · doi:10.1016/j.molimm.2010.11.017 · Cited by 39
Abuqayyas, L., & Balthasar, J. P. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.09.042 · Cited by 35
Molthoff, C., Pinedo, H. M., Schlüper, H., et al. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.144 · Cited by 25
Nishio, S., Yamamoto, T., Kaneko, K., Tanaka-Matsumoto, N., Muraoka, S., Kaburaki, M., Kusunoki, Y., Takagi, K., & Kawai, S. (2009) · Modern Rheumatology · doi:10.1007/s10165-009-0158-0 · Cited by 21
Kairemo, K., Lappalainen, A. K., Kääpä, E., et al. (2001) · PubMed · Cited by 19
Jarnum, S. (1975) · Journal of Clinical Pathology · doi:10.1136/jcp.s1-6.1.13 · Cited by 18
Pharmacokinetics and Pharmacodynamics of Peptide and Protein Therapeutics
Meibohm, B. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6486-0_5 · Cited by 17
Self-citationMonoclonal Antibodies: From Structure to Therapeutic Application
Davis, J. D., Deng, R., Boswell, C. A., Zhang, Y., Li, J., Fielder, P. J., Joshi, A., & Kenkare-Mitra, S. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6486-0_7 · Cited by 17
Cited by
The evolution of commercial drug delivery technologies
Vargason, A. M., Anselmo, A. C., & Mitragotri, S. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00698-w · Cited by 1,361
The pharmacology and therapeutic applications of monoclonal antibodies
Castelli, M. S., McGonigle, P., & Hornby, P. J. (2019) · Pharmacology Research & Perspectives · doi:10.1002/prp2.535 · Cited by 364
Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors
Centanni, M., Moes, D. J. A. R., Trocóniz, I. F., Ciccolini, J., & van Hasselt, J. G. C. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00748-2 · Cited by 355
Structure, Function, and Therapeutic Use of IgM Antibodies
Keyt, B. A., Baliga, R., Sinclair, A. M., Carroll, S. F., & Peterson, M. S. (2020) · Antibodies · doi:10.3390/antib9040053 · Cited by 254
Monoclonal antibody-based molecular imaging strategies and theranostic opportunities
Dammes, N., & Peer, D. (2020) · Theranostics · doi:10.7150/thno.37443 · Cited by 138
Metadata
- Authors
- Ryman, J. T., & Meibohm, B.
- Venue
- CPT: Pharmacometrics & Systems Pharmacology
- Publisher
- Wiley
- Published
- 2017-07-29
- Volume
- 6
- Issue
- 9
- Pages
- 576-588
- ISSN
- 2163-8306 (ISSN-L)
- OpenAlex
- W2728093281
- Cited by
- 802
- References
- 94
- FWCI
- 39.57
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.